In our Reality Check stories, Herald-Leader journalists dig deeper into questions over facts, consequences and accountability. Read more. Story idea? hlcityregion@herald-leader.com. A Lexington police ...

"CLUE" arrives at ASU Gammage this week, bringing the classic board game’s murderous mystery to life. FOX 10’s Anita Roman takes viewers behind the curtain to explore the production's intricate set ...

The Los Angeles Dodgers are in their first week of full-squad Spring Training workouts that are leading up to a Cactus League opener against the Los Angeles Angels on Saturday. That's a road matchup ...

The defending champion Los Angeles Dodgers don’t enter many springs with uncertainty. That’s the luxury of a roster built around stars like Shohei Ohtani, Mookie Betts, and Freddie Freeman, ...

“Buying uranium is suspiciously easy. It shows up in a UPS truck,” says Staff Sheehan, CEO and founder of Project Omega. “You can Google it.” He’s not speaking hypothetically. He’s explaining how his ...

Actor Bud Cort, who played the lead role in the 1971 classic film “Harold and Maude,” has died. He was 77. Cort’s longtime friend Dorian Hannaway reported his death to Variety, saying he died at his ...

Associate Editor Casey Epstein-Gross’s column Cultural Reset features regular deep dives into the impact of music on culture—and vice versa—in the 21st century from the perspective of someone born and ...

The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third ...

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA interference medicines for the common liver condition. Madrigal surprised ...

Get up-to-the-minute news sent straight to your device. Sorry, an error occurred. Already Subscribed! Cancel anytime Account processing issue - the email address may ...

A meta-analysis found that noninvasive imaging tests identified patients with “at-risk” metabolic dysfunction-associated steatohepatitis (MASH) with moderate accuracy, with a FibroScan-based scoring ...